Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTSG NASDAQ:HRMY NASDAQ:PTCT NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTSGBrightSpring Health Services$72.91$65.20$19.01▼$73.40$14.38B1.794.44 million shs2.48 million shsHRMYHarmony Biosciences$35.32$33.95$25.52▼$40.87$2.04B0.94863,409 shs585,339 shsPTCTPTC Therapeutics$76.82$77.19$43.17▼$90.87$6.37B0.531.72 million shs838,164 shsVERAVera Therapeutics$35.45$37.00$19.07▼$56.05$2.54B0.922.37 million shs786,120 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTSGBrightSpring Health Services0.00%+3.14%+5.70%+50.11%+255.14%HRMYHarmony Biosciences0.00%+4.59%-0.42%+13.75%-5.86%PTCTPTC Therapeutics0.00%-2.25%-9.01%+10.98%+71.70%VERAVera Therapeutics0.00%-7.92%-16.51%-4.91%+62.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTSGBrightSpring Health Services$72.91$65.20$19.01▼$73.40$14.38B1.794.44 million shs2.48 million shsHRMYHarmony Biosciences$35.32$33.95$25.52▼$40.87$2.04B0.94863,409 shs585,339 shsPTCTPTC Therapeutics$76.82$77.19$43.17▼$90.87$6.37B0.531.72 million shs838,164 shsVERAVera Therapeutics$35.45$37.00$19.07▼$56.05$2.54B0.922.37 million shs786,120 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTSGBrightSpring Health Services0.00%+3.14%+5.70%+50.11%+255.14%HRMYHarmony Biosciences0.00%+4.59%-0.42%+13.75%-5.86%PTCTPTC Therapeutics0.00%-2.25%-9.01%+10.98%+71.70%VERAVera Therapeutics0.00%-7.92%-16.51%-4.91%+62.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTSGBrightSpring Health Services 3.00Buy$70.12-3.83% DownsideHRMYHarmony Biosciences 2.50Moderate Buy$42.5020.33% UpsidePTCTPTC Therapeutics 2.80Moderate Buy$92.2920.13% UpsideVERAVera Therapeutics 2.77Moderate Buy$84.58138.60% UpsideCurrent Analyst Ratings BreakdownLatest BTSG, PTCT, VERA, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026PTCTPTC Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$95.00 ➝ $93.007/17/2026VERAVera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.007/16/2026PTCTPTC Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$124.00 ➝ $130.007/14/2026BTSGBrightSpring Health Services KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$60.00 ➝ $80.007/14/2026BTSGBrightSpring Health Services Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$71.00 ➝ $80.007/13/2026BTSGBrightSpring Health Services Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$61.00 ➝ $78.007/13/2026BTSGBrightSpring Health Services GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$81.007/13/2026BTSGBrightSpring Health Services GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$81.007/13/2026HRMYHarmony Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/9/2026BTSGBrightSpring Health Services Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.00(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTSGBrightSpring Health Services$12.91B1.11$2.20 per share33.18$10.40 per share7.01HRMYHarmony Biosciences$868.45M2.35$3.18 per share11.11$15.11 per share2.34PTCTPTC Therapeutics$1.73B3.68$8.78 per share8.75($2.56) per share-30.01VERAVera TherapeuticsN/AN/AN/AN/A$8.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTSGBrightSpring Health Services$190.67M$1.4151.7134.230.922.27%14.63%4.41%7/31/2026 (Estimated)HRMYHarmony Biosciences$158.69M$2.4814.249.130.3316.20%17.19%11.99%8/4/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A36.076.69-22.58%-362.45%-6.76%7/30/2026 (Estimated)VERAVera Therapeutics-$299.61M-$5.54N/AN/AN/AN/A-74.86%-60.18%8/4/2026 (Estimated)Latest BTSG, PTCT, VERA, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026HRMYHarmony Biosciences$0.97N/AN/AN/A$249.01 millionN/A8/4/2026Q2 2026VERAVera Therapeutics-$1.60N/AN/AN/A$1.28 millionN/A7/31/2026Q2 2026BTSGBrightSpring Health Services$0.3963N/AN/AN/A$3.66 billionN/A7/30/2026Q2 2026PTCTPTC Therapeutics$0.22N/AN/AN/A$298.63 millionN/A5/7/2026Q1 2026HRMYHarmony Biosciences$0.76$0.55-$0.21$0.55$220.84 million$215.39 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/7/2026Q1 2026VERAVera Therapeutics-$1.3284-$1.69-$0.3616-$1.69$0.43 millionN/A5/1/2026Q1 2026BTSGBrightSpring Health Services$0.29$0.39+$0.10$0.67$3.39 billion$3.61 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTSGBrightSpring Health ServicesN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTSGBrightSpring Health Services1.241.741.38HRMYHarmony Biosciences0.153.583.56PTCTPTC TherapeuticsN/A2.442.36VERAVera Therapeutics0.1513.6413.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTSGBrightSpring Health ServicesN/AHRMYHarmony Biosciences86.23%PTCTPTC TherapeuticsN/AVERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipBTSGBrightSpring Health Services2.80%HRMYHarmony Biosciences11.00%PTCTPTC Therapeutics5.50%VERAVera Therapeutics15.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTSGBrightSpring Health Services23,500197.29 million191.76 millionOptionableHRMYHarmony Biosciences20057.89 million51.53 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableVERAVera Therapeutics4071.78 million60.37 millionOptionableBTSG, PTCT, VERA, and HRMY HeadlinesRecent News About These CompaniesFirst Light Asset Management LLC Lowers Stock Holdings in Vera Therapeutics, Inc. $VERA1 hour ago | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 25 at 2:28 AM | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Moderate Buy" by BrokeragesJuly 25 at 2:28 AM | marketbeat.comFifth Third Bancorp Purchases Shares of 35,492 Vera Therapeutics, Inc. $VERAJuly 24 at 3:43 AM | marketbeat.comJ. Safra Sarasin Holding AG Has $524,000 Stake in Vera Therapeutics, Inc. $VERAJuly 16, 2026 | marketbeat.comVera Therapeutics Inc - Ordinary Shares - Class AJuly 13, 2026 | money.usnews.comAnalysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)July 12, 2026 | theglobeandmail.comCandriam S.C.A. Increases Position in Vera Therapeutics, Inc. $VERAJuly 12, 2026 | marketbeat.comVera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets LaunchJuly 11, 2026 | marketbeat.comVera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% RunJuly 10, 2026 | finance.yahoo.comVera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA ApprovalJuly 10, 2026 | finance.yahoo.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 10, 2026 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 6.8% on Insider SellingJuly 10, 2026 | marketbeat.comQ3 EPS Forecast for Vera Therapeutics Decreased by AnalystJuly 10, 2026 | marketbeat.comMarshall Fordyce Sells 46,250 Shares of Vera Therapeutics (NASDAQ:VERA) StockJuly 10, 2026 | insidertrades.comVera Therapeutics: A Crowded IgAN Market Leaves No Room For A Premium (Downgrade)July 9, 2026 | seekingalpha.comVera Therapeutics (NASDAQ:VERA) CEO Sells $1,956,375.00 in StockJuly 9, 2026 | marketbeat.comVera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William TurnerJuly 9, 2026 | globenewswire.comVera Therapeutics wins FDA nod for closely watched kidney disease drugJuly 8, 2026 | finance.yahoo.comPharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and moreJuly 8, 2026 | statnews.comSFDA grants accelerated approval to Vera Therapeutics' TrutaknaJuly 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026Costco’s Secret Growth Engine May Be Running Out of GasBy Dan Schmidt | June 28, 2026AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space SectorBy Jessica Mitacek | July 17, 2026The Bond Market Just Sent Amazon a Message Investors Shouldn’t IgnoreBy Sam Quirke | July 14, 2026This Edge AI Stock Just Got a Huge Vote of Confidence From Wall StreetBy Thomas Hughes | July 6, 2026BTSG, PTCT, VERA, and HRMY Company DescriptionsBrightSpring Health Services NASDAQ:BTSG$72.91 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$73.28 +0.37 (+0.51%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States. The company's platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It serves patients through clinical providers and pharmacists. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.Harmony Biosciences NASDAQ:HRMY$35.32 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$35.34 +0.02 (+0.06%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.PTC Therapeutics NASDAQ:PTCT$76.82 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$76.74 -0.07 (-0.10%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Vera Therapeutics NASDAQ:VERA$35.45 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$35.50 +0.05 (+0.14%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
